Corcept Therapeutics Incorporated Q3 2025 Earnings Recap

CORT Q3 2025 November 6, 2025

Corcept Therapeutics reported a 13.8% year-over-year revenue increase to $207.6 million in Q3 2025, albeit with a significant drop in net income compared to the prior year. The company remains optimistic about future growth driven by expanding prescribing practices and upcoming product approvals.

Earnings Per Share Miss

$0.16 vs $0.18 est.

-11.1% surprise

Revenue Miss

207638000 vs 255346000 est.

-18.7% surprise

Market Reaction

1-Day -4.68%

5-Day +3.08%

30-Day +4.08%

Key Takeaways

Adjusted 2025 revenue guidance is now between $800 million and $850 million.
Net income decreased to $19.7 million from $47.2 million in Q3 2024.
Korlym prescriptions surged 42.5%, outpacing supply due to capacity constraints; transitioning to a new pharmacy is underway.
Confidence in relacorilant's commercial success, targeting $3 billion to $5 billion in annual revenue within 3-5 years.
Two pivotal NDA applications for relacorilant are nearing their FDA deadlines, with significant clinical trial results anticipated in 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CORT on AllInvestView.